<?xml version="1.0" encoding="UTF-8"?>
<p>Clinical data supporting the use of AS against HCMV are contrasting. In a case report, a rapid decrease in viral load was observed in a stem cell transplant recipient infected with a newly identified foscarnet-resistant and ganciclovir-resistant HCMV strain and treated with AS [
 <xref rid="B12-microorganisms-08-00085" ref-type="bibr">12</xref>]. In this regard, a clinical trial was registered for the use of AS in stem cell transplant recipients, but although the recruitment of 20 patients in Israel has been completed, no results are available yet (
 <xref rid="microorganisms-08-00085-t001" ref-type="table">Table 1</xref>).
</p>
